Where Next For Digital Support Programs?

Is the pharma business model broken? How will pharma firms deliver true value and relevance in the years ahead? What is the step change required?These questions were at the back of my mind when S3 Connected Health and eyeforpharma were working on our joint white paper,Patient Support Programs: Now, Near, Next. We wanted to take the pulse of industry experts on their ‘beyond the pill’ strategy, so we spoke to 20+ senior leaders currently designing and implementing patient support programs (PSPs) from firms including Novartis, AstraZeneca, Sanofi and Takeda.All are mindful of the wider context; hugely expensive drug development and waning return on investment.In response, many firms have invested in PSPs to demonstrate added-value and gather real-world evidence. This makes good strategic sense, with payers increasingly wary of the high costs of new drugs.A new dawn Some clear themes emerged from the interviews conducted for the white paper: Pharma sees the potential to deliver personalized patient-centric services, but is unclear about how to get there Understanding behaviors is key to engaging and motivating patients To deliver meaningful services you must engage clinicians by understanding their challenges and drivers Pharma must be brave and agile, must move beyond the brand, and invest where ROI cannot be guaranteed.‘Traditional’ PSPs – typically involving nurse-led call centers using first-generation digital technologies like texts, alerts and emails del...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news